Look back at pharma news in the week to October 25

27 October 2019

By Barbara Obstoj-Cardwell. Editor

Last week’s research news included a boost on Monday for Seattle Genetics, with positive top-line results for its breast cancer candidate tucatinib, and Biogen surprised when it revealed a new analysis of what seemed to be abandoned Alzheimer’s disease drug aducanumab would now be filed with the US Food and Drug Administration. On the deal-making front, Bavarian Nordic acquired the travel vaccine brands from GlaxoSmithKline for up to 955 million euros. There was also good news last Monday for Vertex Pharma, with the FDA approval for its cystic fibrosis drug Trikafta coming five months earlier than a decision was expected.

Vindication is sweet for Seattle Genetics

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK